{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:56Z","timestamp":1791963956952,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:42:44Z","timestamp":1790034164000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation Using Rabbit Antithymocyte Globulin or Porcine Antihuman T Lymphocyte Immunoglobulin in the Letermovir Era"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7101-4397","authenticated-orcid":false,"given":"Xinyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6226-072X","authenticated-orcid":false,"given":"Huafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2026.09.006_bib0001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)\u2013seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.006_bib0002","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"10.1016\/j.jtct.2026.09.006_bib0003","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2026.09.006_bib0004","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.006_bib0005","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.006_bib0006","article-title":"American Society for Transplantation and Cellular Therapy Series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients","volume":"31","author":"Khawaja","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0008","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41409-024-02433-w","article-title":"Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion","volume":"60","author":"Huang","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.006_bib0011","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/bmt.2012.45","article-title":"Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation","volume":"47","author":"Ruutu","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"10.1016\/j.jtct.2026.09.006_bib0012","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0013","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2026.09.006_bib0014","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-5-46","article-title":"Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies","volume":"5","author":"Xuan","year":"2012","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.006_bib0016","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.bbmt.2015.11.887","article-title":"Viral reactivation in haploidentical transplants using post-transplantation cyclophosphamide \u2013 a single institution experience","volume":"22","author":"Ramlal","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"23","key":"10.1016\/j.jtct.2026.09.006_bib0017","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1182\/bloodadvances.2023010966","article-title":"Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide\u2013based transplant","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0019","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.19205","article-title":"Effectiveness of in vivo T-cell-depleted regimen containing porcine anti-lymphocyte globulin or rabbit anti-thymocyte globulin in preventing acute graft-versus-host disease after haploidentical haematopoietic stem cell transplantation","volume":"204","author":"Xu","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0021","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjh.19958","article-title":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","volume":"206","author":"Zhang","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.09.006_bib0022","article-title":"Retrospective comparison of efficacy and safety of rabbit anti-thymocyte globulin and porcine anti-lymphocyte globulin in patients with acquired aplastic anemia undergoing hematopoietic stem cell transplantation from matched sibling donors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.006_bib0023","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0024","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Schmitt","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.006_bib0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.006_bib0026","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.27619","article-title":"Differential clinical and immunological impacts of anti\u2013T-lymphocyte globulin (ATLG) vs. anti-thymocyte globulin (ATG) in preventing graft-versus-host disease post-allogeneic hematopoietic stem cell transplantation: a comparative study","volume":"100","author":"Notarantonio","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.006_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41409-025-02742-8","article-title":"Usage of rabbit anti-thymocyte \/anti-T-lymphocyte globulins (ATG \/ ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee","volume":"61","author":"Battipaglia","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.006_bib0028","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/ajt.12514","article-title":"A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations","volume":"13","author":"Popow","year":"2013","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0029","first-page":"761","article-title":"A comprehensive analysis of the major specificities of anti-human T lymphocyte porcine immunoglobulin (p-ATG)","volume":"104","author":"Zou","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.006_bib0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","article-title":"Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion","volume":"91","author":"Schmidt-Hieber","year":"2010","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.006_bib0031","first-page":"1020.e1","article-title":"Impact of in vivo lymphodepletion on outcome in children with nonmalignant disorders receiving peripheral blood stem cell transplantation","volume":"27","author":"Ottaviano","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0032","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-021-02410-z","article-title":"Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia","volume":"22","author":"Chen","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/JCI133960","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","author":"Duke","year":"2021","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.006_bib0034","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41409-020-01178-6","article-title":"Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study","volume":"56","author":"Beauvais","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.006_bib0035","first-page":"184.e1","article-title":"Risk-adapted letermovir prophylaxis based on a scoring system predicting a higher burden of cytomegalovirus exposure after allogeneic hematopoietic cell transplantation","volume":"31","author":"Kawamura","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.006_bib0036","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1182\/blood-2008-05-157354","article-title":"Human NK cells can control CMV infection in the absence of T cells","volume":"112","author":"Kuijpers","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.006_bib0037","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2023012008","article-title":"Impaired T cells and \u201cmemory-like\u201d NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation","volume":"8","author":"Lauruschkat","year":"2024","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:58:36Z","timestamp":1791961116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S2666636726007098"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation Using Rabbit Antithymocyte Globulin or Porcine Antihuman T Lymphocyte Immunoglobulin in the Letermovir Era","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}